271 related articles for article (PubMed ID: 33473249)
1. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward.
Lostes-Bardaji MJ; García-Illescas D; Valverde C; Serrano C
Ther Adv Med Oncol; 2021; 13():1758835920986498. PubMed ID: 33473249
[TBL] [Abstract][Full Text] [Related]
2. Ripretinib for the treatment of advanced gastrointestinal stromal tumor.
Zalcberg JR
Therap Adv Gastroenterol; 2021; 14():17562848211008177. PubMed ID: 33948116
[TBL] [Abstract][Full Text] [Related]
3. Emerging drugs for the treatment of gastrointestinal stromal tumors.
Pilco-Janeta DF; García-Valverde A; Gomez-Peregrina D; Serrano C
Expert Opin Emerg Drugs; 2021 Mar; 26(1):53-62. PubMed ID: 33645383
[TBL] [Abstract][Full Text] [Related]
4. Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor.
Bauer S; George S; von Mehren M; Heinrich MC
Front Oncol; 2021; 11():672500. PubMed ID: 34322383
[TBL] [Abstract][Full Text] [Related]
5. Ripretinib and MEK Inhibitors Synergize to Induce Apoptosis in Preclinical Models of GIST and Systemic Mastocytosis.
Gupta A; Singh J; García-Valverde A; Serrano C; Flynn DL; Smith BD
Mol Cancer Ther; 2021 Jul; 20(7):1234-1245. PubMed ID: 33947686
[TBL] [Abstract][Full Text] [Related]
6. Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib: a plain language summary of the phase 3 INTRIGUE trial.
Symcox M; Jones RL
Future Oncol; 2023 Nov; 19(36):2383-2393. PubMed ID: 37594164
[TBL] [Abstract][Full Text] [Related]
7. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.
Mohammadi M; Gelderblom H
Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274
[No Abstract] [Full Text] [Related]
8. Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors.
Sargsyan A; Kucharczyk MA; Jones RL; Constantinidou A
Expert Rev Gastroenterol Hepatol; 2023 Feb; 17(2):119-127. PubMed ID: 36644853
[TBL] [Abstract][Full Text] [Related]
9. Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.
Smith BD; Kaufman MD; Lu WP; Gupta A; Leary CB; Wise SC; Rutkoski TJ; Ahn YM; Al-Ani G; Bulfer SL; Caldwell TM; Chun L; Ensinger CL; Hood MM; McKinley A; Patt WC; Ruiz-Soto R; Su Y; Telikepalli H; Town A; Turner BA; Vogeti L; Vogeti S; Yates K; Janku F; Abdul Razak AR; Rosen O; Heinrich MC; Flynn DL
Cancer Cell; 2019 May; 35(5):738-751.e9. PubMed ID: 31085175
[TBL] [Abstract][Full Text] [Related]
10. Fourth-line rescue treatment ripretinib of advanced small intestine gastrointestinal stromal tumors who achieved partial response: a case report.
Liu B; Kou Y
J Gastrointest Oncol; 2022 Jun; 13(3):1505-1513. PubMed ID: 35837161
[TBL] [Abstract][Full Text] [Related]
11. 2023 GEIS Guidelines for gastrointestinal stromal tumors.
Serrano C; Martín-Broto J; Asencio-Pascual JM; López-Guerrero JA; Rubió-Casadevall J; Bagué S; García-Del-Muro X; Fernández-Hernández JÁ; Herrero L; López-Pousa A; Poveda A; Martínez-Marín V
Ther Adv Med Oncol; 2023; 15():17588359231192388. PubMed ID: 37655207
[TBL] [Abstract][Full Text] [Related]
12. Ripretinib in treatment of repeatedly relapsing rectal gastrointestinal stromal tumor: a case report.
Wu C; Zhang J; Wu X
Ann Palliat Med; 2021 Apr; 10(4):4994-4998. PubMed ID: 33966435
[TBL] [Abstract][Full Text] [Related]
13. Ripretinib for the treatment of advanced, imatinib-resistant gastrointestinal stromal tumors.
Liu WZ; Du YQ; Shen Q; Tao KX; Zhang P
J Dig Dis; 2023 Sep; ():. PubMed ID: 37706279
[TBL] [Abstract][Full Text] [Related]
14. Emerging Data on the Safety and Efficacy of Ripretinib for the Treatment of Gastrointestinal Stromal Tumors.
Thirasastr P; Somaiah N
Clin Exp Gastroenterol; 2023; 16():11-19. PubMed ID: 36798653
[TBL] [Abstract][Full Text] [Related]
15. Preclinical model-based evaluation of Imatinib resistance induced by
Zhao Q; Zhang C; Qi C; Yang J; Chen Y; Ge S; Shen L; Gao J; Li J
Am J Transl Res; 2021; 13(12):13608-13624. PubMed ID: 35035701
[TBL] [Abstract][Full Text] [Related]
16. New treatment strategies for advanced-stage gastrointestinal stromal tumours.
Klug LR; Khosroyani HM; Kent JD; Heinrich MC
Nat Rev Clin Oncol; 2022 May; 19(5):328-341. PubMed ID: 35217782
[TBL] [Abstract][Full Text] [Related]
17. Liquid Biopsy in Gastrointestinal Stromal Tumors: Ready for Prime Time?
Gómez-Peregrina D; García-Valverde A; Pilco-Janeta D; Serrano C
Curr Treat Options Oncol; 2021 Feb; 22(4):32. PubMed ID: 33641024
[TBL] [Abstract][Full Text] [Related]
18. Combination of Type I and II tyrosine kinase inhibitors-avapritinib and sunitinib-in refractory gastrointestinal stromal tumor after failure to multi-line therapy: a case report.
Guo X; Huang S; Shi Y; Guan Z; Chen S; Feng Y; Xia Y; Zhang X
Ann Transl Med; 2022 Sep; 10(18):1026. PubMed ID: 36267752
[TBL] [Abstract][Full Text] [Related]
19. Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors.
Serrano C; Vivancos A; López-Pousa A; Matito J; Mancuso FM; Valverde C; Quiroga S; Landolfi S; Castro S; Dopazo C; Sebio A; Virgili AC; Menso MM; Martín-Broto J; Sansó M; García-Valverde A; Rosell J; Fletcher JA; George S; Carles J; Arribas J
BMC Cancer; 2020 Feb; 20(1):99. PubMed ID: 32024476
[TBL] [Abstract][Full Text] [Related]
20. Genotyping guided ripretinib directly after the progression of first-line imatinib therapy in advanced gastrointestinal stromal tumor: a case report.
Huang S; Guo X; Xia Y; Ding L; Zhai E; Chen S; He Y; Cai S; Zhang X
Ann Transl Med; 2022 Jan; 10(2):118. PubMed ID: 35282043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
